Quince Therapeutics, Inc. 8-K

What Happened

• Quince Therapeutics, Inc. announced that it has regained compliance with Nasdaq listing requirements. On March 17, 2026 the company had received a Nasdaq notice for failing to meet the minimum market value of listed securities (MVLS) of $50,000,000 over 30 business days.
• On May 20, 2026 Nasdaq informed the company that, based on its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (which reported stockholders’ equity of $15,672,000), Quince now meets Nasdaq Listing Rule 5450(b)(1)(A), and the matter is closed.

Key Details

• Nasdaq MVLS deficiency notice received: March 17, 2026 (Nasdaq Listing Rule 5450(b)(2)(A)).
• Nasdaq confirmation of compliance: May 20, 2026.
• Source of compliance: Form 10-Q for quarter ended March 31, 2026 reporting stockholders’ equity of $15,672,000.
• Result: Company regained compliance with Nasdaq Global Market listing requirements; matter closed.

Why It Matters

• For investors, the company’s regained compliance means Quince’s common stock remains listed on the Nasdaq Global Market, avoiding delisting risk tied to the previous MVLS shortfall.
• The filing points to the company meeting the alternative Nasdaq equity-based criterion (stockholders’ equity), rather than demonstrating a $50M market value, which is a material regulatory development but does not by itself address operating or revenue performance.